8 results
424B5
SMTI
Sanara MedTech Inc
16 Feb 21
Prospectus supplement for primary offering
4:52pm
the submission and approval of a PMA application. Under the Food and Drug Administration Safety and Innovation Act of 2012 (“FDASIA”), the FDA is required
424B5
SMTI
Sanara MedTech Inc
11 Feb 21
Prospectus supplement for primary offering
4:06pm
and Innovation Act of 2012 (“FDASIA”), the FDA is required to classify a device within 120 days following receipt of the de novo classification request
8-K
EX-17.1
2nk1d3iv
5 Mar 15
Departure of Directors or Certain Officers
12:00am
- Prev
- 1
- Next